The U.S. Food and Drug Administration (FDA) has approved Danish drugmaker Novo Nordisk’s semalutide (NOVOb.CO) once a week to treat obesity. It is a condition that affects nearly 70% of American adults.
The drugmaker said it expected to launch the drug, which will be sold under the brand name Wegovy, in the United States in late June 2021.
The regulatory nod is a big win for Novo, which has seen its core insulin business face stiff competition. Encouraged to turn to new diabetes and diet pills to regain growth.
Novo’s revenue growth was driven by sales of its next-generation GLP-1 product, which mimics the intestinal hormone that stimulates insulin production. decreased appetite and increase the feeling of fullness in patients
Doug Langa, Novo’s executive vice president of North American operations, told Reuters on Thursday. “There was a lot of unmet demand” ahead of the FDA’s decision.
Langa hopes the enhanced performance of the semalutide will help Novo continue to grow in the market. especially by convincing more doctors to prescribe the drug. At the same time, it allows insurance companies to include more of the drug in their coverage.
Novo, the first company to introduce GLP-1 in the obesity market It could benefit from more competitors entering the field to help treat branded obesity drugs among general practitioners.
FDA approves 2.4 mg semalutide to treat obese adults It’s an adjunct to exercise and a low-calorie diet, Novo says.
The subcutaneous injection was the first drug approved for chronic weight management in obese or overweight adults since 2014, the FDA said (https://bit.ly/34OdzdH).
Novo is preparing for the launch of semalutide, with about 350 to 400 dealers ready to sell the product, Langa said, but he declined to disclose how much Novo expects to spend on marketing.
Our Standard: Thomson Reuters Trust Principles